Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction

The report reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Adenocarcinoma Of The Gastroesophageal Junction therapeutics and enlists all their major and minor projects

The report assesses Adenocarcinoma Of The Gastroesophageal Junction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Advenchen Laboratories, LLC

Amgen Inc.

ArQule, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cerulean Pharma, Inc.

Daiichi Sankyo Company, Limited

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Ganymed Pharmaceuticals AG

Genentech Inc

Gilead Sciences, Inc.

Hutchison MediPharma Limited

Imugene Limited

Mebiopharm Co., Ltd.

MedImmune LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Neopharm Ltd.

Novartis AG

Oncobiologics, Inc.

Panacea Biotec Limited

Sanofi

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Adenocarcinoma Of The Gastroesophageal Junction Overview 8

Therapeutics Development 9

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 9

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 10

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 11

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes 13

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17

Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes 20

Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 21

AB Science SA 21

AbbVie Inc 22

Advenchen Laboratories, LLC 23

Amgen Inc. 24

ArQule, Inc. 25

AstraZeneca Plc 26

Boehringer Ingelheim GmbH 27

Boston Biomedical, Inc. 28

Bristol-Myers Squibb Company 29

Cerulean Pharma, Inc. 30

Daiichi Sankyo Company, Limited 31

Dr. Reddy's Laboratories Limited 32

Eli Lilly and Company 33

F. Hoffmann-La Roche Ltd. 34

Ganymed Pharmaceuticals AG 35

Genentech Inc 36

Gilead Sciences, Inc. 37

Hutchison MediPharma Limited 38

Imugene Limited 39

Mebiopharm Co., Ltd. 40

MedImmune LLC 41

Merck & Co., Inc. 42

Merck KGaA 43

Millennium Pharmaceuticals Inc 44

Neopharm Ltd. 45

Novartis AG 46

Oncobiologics, Inc. 47

Panacea Biotec Limited 48

Sanofi 49

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 50

Assessment by Monotherapy Products 50

Assessment by Combination Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

AL-3818 - Drug Profile 62

alpelisib - Drug Profile 64

AMG-337 - Drug Profile 67

atezolizumab - Drug Profile 69

avelumab - Drug Profile 83

AZD-4547 - Drug Profile 94

AZD-6738 - Drug Profile 96

BI-853520 - Drug Profile 97

cabazitaxel - Drug Profile 98

catumaxomab - Drug Profile 100

Cellular Immunotherapy for Oncology - Drug Profile 102

ceritinib - Drug Profile 103

CRLX-101 - Drug Profile 108

DS-8201 - Drug Profile 119

durvalumab - Drug Profile 120

durvalumab + tremelimumab - Drug Profile 131

emibetuzumab - Drug Profile 135

GS-5745 - Drug Profile 137

ibrutinib - Drug Profile 139

IMAB-362 - Drug Profile 165

IMU-131 - Drug Profile 167

ipatasertib - Drug Profile 171

ipilimumab - Drug Profile 173

JS-001 - Drug Profile 182

LAG-525 - Drug Profile 183

LY-3127804 - Drug Profile 184

masitinib - Drug Profile 185

merestinib - Drug Profile 199

napabucasin - Drug Profile 201

nimotuzumab - Drug Profile 208

oxaliplatin - Drug Profile 212

panitumumab - Drug Profile 214

PDR-001 - Drug Profile 219

pembrolizumab - Drug Profile 221

pertuzumab - Drug Profile 258

ramucirumab - Drug Profile 264

SAR-408701 - Drug Profile 274

savolitinib - Drug Profile 275

serabelisib - Drug Profile 279

sonidegib phosphate - Drug Profile 281

tivantinib - Drug Profile 285

trastuzumab biosimilar - Drug Profile 291

trastuzumab biosimilar - Drug Profile 293

trastuzumab biosimilar - Drug Profile 294

trastuzumab biosimilar - Drug Profile 295

trastuzumab biosimilar - Drug Profile 296

tremelimumab - Drug Profile 297

Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 300

Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 302

Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 303

Featured News & Press Releases 303

Appendix 316

Methodology 316

Coverage 316

Secondary Research 316

Primary Research 316

Expert Panel Validation 316

Contact Us 316

Disclaimer 317

List of Tables

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Development by Companies, H2 2016 (Contd..2) 22

Products under Investigation by Universities/Institutes, H2 2016 23

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by AB Science SA, H2 2016 24

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by AbbVie Inc, H2 2016 25

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Advenchen Laboratories, LLC, H2 2016 26

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Amgen Inc., H2 2016 27

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by ArQule, Inc., H2 2016 28

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by AstraZeneca Plc, H2 2016 29

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Boehringer Ingelheim GmbH, H2 2016 30

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Boston Biomedical, Inc., H2 2016 31

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Bristol-Myers Squibb Company, H2 2016 32

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Cerulean Pharma, Inc., H2 2016 33

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 35

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Eli Lilly and Company, H2 2016 36

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Ganymed Pharmaceuticals AG, H2 2016 38

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Genentech Inc, H2 2016 39

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Gilead Sciences, Inc., H2 2016 40

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Hutchison MediPharma Limited, H2 2016 41

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Imugene Limited, H2 2016 42

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Mebiopharm Co., Ltd., H2 2016 43

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by MedImmune LLC, H2 2016 44

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Merck & Co., Inc., H2 2016 45

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Merck KGaA, H2 2016 46

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 47

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Neopharm Ltd., H2 2016 48

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Novartis AG, H2 2016 49

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Oncobiologics, Inc., H2 2016 50

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Panacea Biotec Limited, H2 2016 51

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline by Sanofi, H2 2016 52

Assessment by Monotherapy Products, H2 2016 53

Assessment by Combination Products, H2 2016 54

Number of Products by Stage and Target, H2 2016 56

Number of Products by Stage and Mechanism of Action, H2 2016 59

Number of Products by Stage and Route of Administration, H2 2016 62

Number of Products by Stage and Molecule Type, H2 2016 64

Adenocarcinoma Of The Gastroesophageal Junction – Dormant Projects, H2 2016 303

Adenocarcinoma Of The Gastroesophageal Junction – Dormant Projects (Contd..1), H2 2016 304

Adenocarcinoma Of The Gastroesophageal Junction – Discontinued Products, H2 2016 305

List of Figures

List of Figures

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 18

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Top 10 Targets, H2 2016 55

Number of Products by Stage and Top 10 Targets, H2 2016 55

Number of Products by Top 10 Mechanism of Actions, H2 2016 58

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 58

Number of Products by Routes of Administration, H2 2016 61

Number of Products by Stage and Routes of Administration, H2 2016 61

Number of Products by Molecule Types, H2 2016 63

Number of Products by Stage and Molecule Types, H2 2016 63

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared